De Bruyn
Alex De Bruyn, Leuven BE
Patent application number | Description | Published |
---|---|---|
20080276000 | System and Method for Distributing Content via a Shared Network - Bandwidth use between an access provider system ( | 11-06-2008 |
Danny De Bruyn, Roosdaal BE
Patent application number | Description | Published |
---|---|---|
20100307954 | BASIC CONTAINER AND CONTAINER COMPRISING A TOP CUP AND THE BASIC CONTAINER - A basic container comprising a top, a substantially flat bottom and at least three substantially flat sides at an angle of substantially 90° with respect to the bottom, the basic container being leak-free except for a container head in the top with a filling/emptying opening and a means for providing a leak-free closure with a closure means, wherein the axis of the container head is at an acute angle with respect to the bottom; a process for the manufacturing thereof; a top cup adapted to be attachable to the top of the above-described basic container without obstructing the filling/emptying opening of the container head of the basic container; and a plastic container comprising the above-described basic container and the above-described top cup attached with attachable means to the basic container, wherein the top cup does not obstruct the opening of the container head. | 12-09-2010 |
Guy De Bruyn, Swiftwater, PA US
Patent application number | Description | Published |
---|---|---|
20160120968 | Compositions and Methods for Immunizing Against C. Difficile - This disclosure relates to methods for eliciting an immune response against | 05-05-2016 |
Henricus Willem M. De Bruyn, Arnhem NL
Patent application number | Description | Published |
---|---|---|
20100145404 | T-WAVE ALTERNANS TRAIN SPOTTER - A method and system for detecting T-wave alternans for use in an implanted medical device uses wave transformation of QT intervals to obtain a reliable measure of TWA. In one embodiment, an array provides alternating sign multiplication factors which are applied respectively to n consecutive QT values. Each successive QT value is high pass filtered and moved sequentially through a queue so that each cycle each of the n QT values is multiplied by one of the factors; the products are summed and made absolute to provide an alternans match value. The alternans match is compared with a noise threshold signal, and alternans is declared when the match exceeds the threshold by a predetermined amount. The array is programmable and can be varied, providing a high degree of flexibility to optimize the test for the patient. | 06-10-2010 |
Hugo De Bruyn, Lennik BE
Patent application number | Description | Published |
---|---|---|
20110171143 | Method of maintaining oral health in animals - Use of a compound having the formula (I) in the manufacture of a medicament for the prevention or treatment of a disease caused by oral bacteria in an animal wherein R1 is a straight or branched alkyl group containing 8 to 16 carbon atoms at the 2- or 3-position of the morpholiπo ring, and R2 is a straight or branched alkyl group containing 2 to 10 carbon atoms, substituted with a hydroxy group except in the alpha-position, or a pharmaceutically acceptable salt thereof. | 07-14-2011 |
20110268671 | Method of Maintaining Oral Health in Animals - Use of a compound having the formula (I) in the manufacture of a medicament for the prevention or treatment of a diseased caused by oral bacterial in an animal Formula (I); wherein R | 11-03-2011 |
20150231048 | Method of Maintaining Oral Health in Animals - Use of a compound having the formula (I) in the manufacture of a medicament for the prevention or treatment of a diseased caused by oral bacterial in an animal Formula (I); wherein R | 08-20-2015 |
Huub De Bruyn, Da Borne NL
Patent application number | Description | Published |
---|---|---|
20160138418 | METHOD FOR OPERATING A TURBOMACHINE, WHEREIN AN EFFICIENCY CHARACTERISTIC VALUE OF A STAGE IS DETERMINED, AND TURBOMACHINE HAVING A DEVICE FOR CARRYING OUT THE METHOD - A turbo-machine, which can be operated in an optimized driving range is provided. To this end, a method for operating a turbo-machine having at least one turbo-machine stage, which has at least one rotary shaft is disclosed. According to the method, the following method steps are carried out: a) determining a desired efficiency characteristic value η | 05-19-2016 |
Marcel F.l. De Bruyn, Beerse BE
Patent application number | Description | Published |
---|---|---|
20080287397 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group - An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved. | 11-20-2008 |
20110130364 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP - An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved. | 06-02-2011 |
Marcel Frans Leopold De Bruyn, Wortel BE
Patent application number | Description | Published |
---|---|---|
20080227791 | Piperidin-4-Yl-Pyridazin-3-Ylamine Derivatives as Fast Dissociating Dopamine 2 Receptor Antagonists - The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects. | 09-18-2008 |
20090253691 | TRISUBSTITUTED 1,2,4-TRIAZOLES - The present invention relates to 3-aniline-5-aryl triazole derivatives and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I). | 10-08-2009 |
20100216846 | TRISUBSTITUTED 1,2,4 TRIAZOLES - The present invention relates to substituted 1-(alkyl)-3-aniline-5-aryl triazole derivatives and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I). | 08-26-2010 |
Marcel Frans, Leopold De Bruyn, Beerse BE
Patent application number | Description | Published |
---|---|---|
20150141432 | PIPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS - The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects. | 05-21-2015 |
Mario De Bruyn, York GB
Patent application number | Description | Published |
---|---|---|
20150065698 | MICROWAVE ASSISTED CITRUS WASTE BIOREFINERY - There is described a method of isolating one or more of pectin, d-limonene, a flavour compound, a flavonoid, a soluble monosaccharide, a decomposition product of a monosaccharide and cellulose, from citrus material wherein said method comprises the microwave assisted hydrothermal low temperature treatment of citrus material. | 03-05-2015 |
Pierre-Henry De Bruyn, Hong Kong CN
Patent application number | Description | Published |
---|---|---|
20120259614 | TRANSLITERATING METHODS BETWEEN CHARACTER-BASED AND PHONETIC SYMBOL-BASED WRITING SYSTEMS - This invention concerns a method for transliterating an at least partially phonetic symbol-based writing system including entry of symbols into a complex character-based writing system including characters, comprising: | 10-11-2012 |
Steven De Bruyn, Baal BE
Patent application number | Description | Published |
---|---|---|
20140212417 | PROLONGED INHIBITION OF INTERLEUKIN-6 MEDIATED SIGNALING - Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling. | 07-31-2014 |
20150050268 | PROLONGED INHIBITION OF INTERLEUKIN-6 MEDIATED SIGNALING - Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling. | 02-19-2015 |